SuperworthAmgen profit margin AMGN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 23.0%
- Operating margin, 12 months
- 30.0%
- Net margin on a year earlier
- +4.0 pts
- Peer median
- 8.3%
Over the twelve months to Jun 30, 2026, Amgen kept 23.0% of its revenue as net profit, with an operating margin of 30.0% and a gross margin of 69.5%.
Five years earlier its net margin was 22.5%.
The median for 8 large drugmakers of a similar size is 8.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 21.0% | 24.7% | 67.2% |
| FY2024 | 12.2% | 21.7% | 61.5% |
| FY2023 | 23.8% | 28.0% | 70.0% |
| FY2022 | 24.9% | 36.3% | 75.7% |
| FY2021 | 22.7% | 29.4% | 75.2% |
| FY2020 | 28.6% | 35.9% | 75.8% |
| FY2019 | 33.6% | 41.4% | 81.4% |
| FY2018 | 35.3% | 43.2% | 82.7% |
| FY2017 | 8.7% | 43.6% | 82.2% |
| FY2016 | 33.6% | 42.6% | 81.9% |
| FY2015 | 32.0% | 39.1% | 80.5% |
| FY2014 | 25.7% | 30.9% | 78.0% |
| FY2013 | 27.2% | 31.4% | 82.1% |
| FY2012 | 25.2% | 32.3% | 81.5% |
| FY2011 | 23.6% | 27.7% | 84.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 23.0% | +4.0 pts | 30.0% | |
| Q1 FY26 | 21.0% | +3.6 pts | 28.4% | |
| Q4 FY25 | 21.0% | +8.7 pts | 24.7% | |
| Q3 FY25 | 19.5% | +6.5 pts | 24.1% | |
| Q2 FY25 | 19.0% | +8.8 pts | 23.5% | |
| Q1 FY25 | 17.4% | +4.6 pts | 21.8% | |
| Q4 FY24 | 12.2% | −11.6 pts | 21.7% | |
| Q3 FY24 | 13.0% | −15.2 pts | 19.1% | |
| Q2 FY24 | 10.1% | −19.9 pts | 20.0% | |
| Q1 FY24 | 12.7% | −17.5 pts | 23.6% | |
| Q4 FY23 | 23.8% | −1.1 pts | 28.0% | |
| Q3 FY23 | 28.2% | +2.2 pts | 33.0% |
Against its peers
Companies in Drug Manufacturers - General nearest Amgen's size, closest first, today.
| Company | Profit margin |
|---|---|
| AMGNAmgen | 23.0% |
| GILDGilead Sciences | −10.6% |
| PFEPfizer | 6.8% |
| MRKMerck | 4.8% |
| BMYBristol-Myers Squibb | 18.9% |
| ABBVAbbVie | 9.8% |
| JNJJohnson & Johnson | n/m |
| LLYEli Lilly and | 33.5% |
| BIIBBiogen | 8.3% |
| Peer median | 8.3% |
Where Amgen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Amgen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.